The Medical Advisor

OneDayMD Master Evidence Guide • Updated September 2026 Semaglutide, tirzepatide, oral GLP-1 medicines, retatrutide and the next generation of metabolic therapies have changed the obesity and cardiometabolic treatment landscape. But the phrase “GLP-1 drug” can hide major differences in mechanism, indication, dose, study population and clinical evidence. This master guide organizes the most important clinical trials into an ebook-style reference—from the landmark STEP and SURMOUNT obesity trials to SELECT , FLOW , SUMMIT , ESSENCE , OASIS 4 , ATTAIN-1 , TRIUMPH, SURPASS  and the emerging CagriSema program. 2026 update: The field has moved beyond injections alone. Oral semaglutide (Wegovy tablets) and orforglipron (Foundayo) are now U.S. FDA-approved options for weight management, while higher-dose semaglutide (Wegovy HD) has also ...

Wearable healthcare is entering a new phase. The first generation of wearables primarily counted steps, estimated calories, measured heart rate and tracked sleep. The next generation is moving toward continuous physiological monitoring, biochemical sensing, artificial intelligence, digital biomarkers, remote patient monitoring and increasingly hands-free interaction. In 2026, the most important development is not simply that wearables can collect more data. It is that different sensors can increasingly be combined with software and AI to interpret patterns over time. That creates the possibility of moving from tracking health toward understanding health in context . At the same time, important limitations remain. A wearable measurement is not automatically a medical diagnosis. Accuracy varies by device, sensor, population and use case, while proprietary algorithms, data privacy, calibration, adherence and clinical validation remain major challenges. A 2026 U.S. Gover...